Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA02 - RET and Novel Combinations of Osimertinib

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      MA02.04 - Discussant

      09:45 - 10:00  |  Presenter: Shengxiang (Harry) Ren

      • Abstract

      No abstract available for this presentation

  • +

    P41 - Multimodality of Advanced Lung Cancer - Clinical Trials, Case Report

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P41.01 - Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial

      00:00 - 00:00  |  Presenter: Chuchu Shao

      • Abstract

      Loading...

  • +

    P66 - Small Cell Lung Cancer/ NET - Pre-Clinical

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Small Cell Lung Cancer/ NET
    • +

      P66.06 - GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis

      00:00 - 00:00  |  Presenter: qian liu

      • Abstract

      Loading...

  • +

    MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

      17:30 - 17:35  |  Presenter: Shengxiang (Harry) Ren

      • Abstract

      Loading...